Black Diamond Therapeutics (BDTX) Soars 1.60% to March 2025 High

Black Diamond Therapeutics, Inc. (BDTX) shares surged 1.60% today, marking the third consecutive day of gains, with a cumulative increase of 15.45% over the past three days. The stock price reached its highest level since March 2025, with an intraday gain of 5.20%.

The strategy of buying BDTX shares after they reach a recent high and holding for one week resulted in poor performance over the past five years. The strategy yielded a return of -38.01%, significantly underperforming the benchmark return of 50.09%. The excess return was -88.10%, and the CAGR was -18.08%, indicating substantial losses. The strategy also had a high maximum drawdown of -80.98% and a Sharpe ratio of -0.15, suggesting significant risk and negative returns.

Recent volatility in Black Diamond Therapeutics' stock price has been a significant factor influencing its performance. The company's shares have experienced notable fluctuations, reflecting the dynamic nature of the market and investor sentiment.

Analysts have provided short-term price targets for Black Diamond Therapeutics, with an average target of $10.67. The range of these targets spans from $9.00 to $15.00, indicating a mix of optimistic and cautious views among market experts. Stifel, in particular, maintains a buy rating with a target price of $15.00, suggesting a strong belief in the company's potential for growth.

Shareholder transactions have also played a role in shaping the stock's trajectory. On March 19, 2025, BIOTECH GROWTH NV, a 10% shareholder, sold 5.78 million shares at an average price of $2.0742, totaling $12 million. This significant transaction could have impacted investor confidence and contributed to the recent volatility in the stock price.